Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Early Breast Cancer Condition: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, high risk of recurrence |
Dose: Tablet – 150 mg Frequency: twice daily Duration: Continue for 2 years, or until disease recurrence or unacceptable toxicity Note: In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) by mouth. |
|
Indication: Advanced or Metastatic Breast Cancer Condition: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, disease progression following endocrine therapy and prior chemotherapy in metastatic setting |
Dose: Tablet – 200 mg Frequency: twice daily Duration: Continue until disease progression or unacceptable toxicity Note: Monotherapy by mouth. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Form – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild or moderate renal impairment (Creatinine Clearance 30-89 mL/min) |
Dose: Not specified Note: No dose adjustment required |
|
Condition: Severe renal impairment, End Stage Renal Disease, or dialysis |
Dose: Not specified Note: Not studied |
Administration
- Take with or without food
- Take at same times daily
Side Effect
- Creatinine increased (98%)
- Diarrhea (90%)
- Decreased WBCs (91%)
- Decreased neutrophil count (88%)
- Anemia (68%)
- Fatigue (65%)
- Nausea (64%)
- Decreased appetite (45%)
- Decreased lymphocyte count (42%)
- Decreased platelet count (41%)
- Abdominal pain (39%)
- Neutropenia (37%)
- Vomiting (35%)
- Infection (31%)
- ALT increased (31%)
- AST increased (30%)
- Decreased WBC, grade 3 (28%)
- Anemia (25%)
- Decreased neutrophil count, grade 3 (22%)
- Thrombocytopenia (20%)
- Diarrhea, grade 3 (20%)
- Headache (20%)
- Cough (19%)
- Neutropenia, grade 3 (19%)
- Constipation (17%)
- Leukopenia (17%)
- Arthralgia (15%)
- Dry mouth (14%)
- Stomatitis (14%)
- Weight decreased (14%)
- Decreased lymphocyte count, grade 3 (13%)
- Dysgeusia (12%)
- Alopecia (12%)
- Dizziness (11%)
- Pyrexia (11%)
- Creatinine increased (98%)
- Decreased WBCs (90%)
- Decreased neutrophil count (80-87%)
- Diarrhea (86%)
- Anemia (29-82%)
- Decreased lymphocyte count (53-63%)
- Decreased platelet count (36-53%)
- Neutropenia (46%)
- Fatigue (46%)
- Nausea (45%)
- Infections (43%)
- ALT increased (13-41%)
- AST increased (12-37%)
- Abdominal pain (35%)
- Decreased neutrophil count, grade 3 (29%)
- Leukopenia (28%)
- Decreased appetite (27%)
- Vomiting (26%)
- Neutropenia, grade 3 (24%)
- Decreased WBC, grade 3 (23%)
- Headache (20%)
- Dysgeusia (18%)
- Thrombocytopenia (16%)
- Alopecia (16%)
- Stomatitis (15%)
- Pruritus (13%)
- Diarrhea, grade 3 (13%)
- Cough (13%)
- Dizziness (12%)
- Decreased lymphocyte count, grade 3 (7-12%)
- Peripheral edema (12%)
- Rash (11%)
- Pyrexia (11%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Ketoconazole
|
Avoid coadministration
|
|
Strong CYP3A inhibitors
|
Decrease recommended starting dose
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.